Zura Bio Ltd
ZURANext catalyst
Tibulizumab
Systemic Sclerosis (SSc)
Get an email about ZURA's next catalysts
Track Zura Bio (ZURA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 1 past
ZURA Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.22 | FQ end Sep/2026 | Call: tbd
Tibulizumab Phase 2 Est. Readout
Primary completion for Tibulizumab trial (NCT06843239) in Systemic Sclerosis (SSc)
SourceHow ZURA's past catalysts played out
Market Overview
Stock performance and key metrics
Tibulizumab Dose A
Hidradenitis Suppurativa (HS)
Tibulizumab
Systemic Sclerosis (SSc)
Tibulizumab Dose B
Hidradenitis Suppurativa (HS)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Tibulizumab Dose A | Phase 2 | Hidradenitis Suppurativa (HS) | - | - |
Tibulizumab | Phase 2 | Systemic Sclerosis (SSc) | - | - |
Tibulizumab Dose B | Phase 2 | Hidradenitis Suppurativa (HS) | - | - |
Frequently asked questions
What is in Zura Bio Ltd's drug pipeline?→
CatalystAlert tracks 3 drug candidates in Zura Bio Ltd's (ZURA) pipeline across Phase 2. Its lead program is Tibulizumab (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Zura Bio Ltd's next FDA catalyst?→
Zura Bio Ltd's (ZURA) next tracked catalyst is a Phase 2 readout expected May 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ZURA biotech catalysts?→
Add ZURA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Zura Bio Ltd's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.